Accelerate Your Discovery Pipeline,
The CeMM Molecular Discovery Platform provides high-end, cost effective analytical services for academic researchers, biotech companies and pharmaceutical partners.
We use a technology-driven approach to empower the discovery and characterization of bioactive molecules, including proteins, metabolites, and novel synthetic compounds.
These three classes of molecules are also the focus of the three modules that constitute the CeMM Molecular Discovery Platform – Chemical Screening, Metabolomics, and Proteomics.
Our Services
• Chemical Screening – screening and profiling of novel synthetic compounds and small molecules
• Metabolomics – sensitive detection and analysis of metabolites from diverse biological samples
• Proteomics – comprehensive protein identification, quantification, and characterization
Using cutting-edge technologies, we maximize molecular coverage while generating robust data from minimal sample amounts.
Interested?
Contact the CeMM Molecular Discovery Platform to discuss your project.
Stefan Kubicek
Biosketch
Stefan Kubicek, born in 1978, is Austrian and joined CeMM in 2010. He obtained an MSc in synthetic organic chemistry from the Vienna University of Technology after writing a diploma thesis at ETH Zurich. For his PhD in Thomas Jenuwein’s lab at the IMP in Vienna, he changed fields to molecular biology and developed the first selective histone methyl transferase inhibitors. He then performed postdoctoral research, working on chemical biology with Stuart Schreiber at the Broad Institute of Harvard and MIT. At CeMM, Stefan Kubicek headed the Christian Doppler Laboratory for Chemical Epigenetics and Antiinfectives, a public-private partnership between CeMM, Boehringer Ingelheim, and Haplogen and is now the head of the CeMM Molecular Discovery Platform. The Kubicek lab is working on the role of chromatin in the definition of cell types and cell states, particularly chromatin-modifying enzymes as synthetic lethal targets in cancer and chemical transdifferentiation to insulin-producing beta cells. In an ERC-funded project, the laboratory studies metabolic enzymes in the cell’s nucleus to test the hypothesis that small molecule metabolites shape chromatin structure and thus control gene expression and cell identity.
Contact
+43 1 40160 70036
Send an e-mail
Stefan Kubicek's Research Group
